
CLAIMS

1. A compound of Formula (~~A~~Id), or a pharmaceutically acceptable salt thereof,



(~~A~~Id)


wherein:

R^1 is~~ selected from~~



~~and~~or ;

R^2 is~~ selected from~~



;

~~R^3 and~~ R^4 ~~are each independently selected from~~ is H, Me, Et, optionally substituted C_1-C_6 alkyl ~~and~~ or optionally substituted C_3-C_6 cycloalkyl;

Y is N(Me)COMe, N(R^5)COMe, N(Me)COR^6, N(R^5)COR^6~~,~~ or CONMe$_2$~~ or a 5-membered *N*-heterocycle such as 1,2,3-triazole and~~;

Z is H~~, Me, Et and optionally substituted C_1-C_6 alkyl~~; or

Y and Z combine to form an optionally substituted 4-, 5- or 6-membered ring;~~

X is ~~selected from~~ OR^7 ~~and~~ or NR^{8}R^9;

R^5 is ~~selected from~~ H, optionally substituted C_1-C_6 alkyl ~~and~~ or optionally substituted C_3-C_6 cycloalkyl;


R^6 is ~~selected from~~ optionally substituted C_1-C_6 alkyl, optionally substituted C_3-C_6 cycloalkyl ~~and~~ or an optionally substituted 5- or 6-membered saturated *N*-heterocycle;

R^7 is Me, Et, *i*-propyl, *n*-propyl, cyclopropyl, cyclobutyl, an optionally substituted C_1-C_6 alkyl, C_3-C_6 cycloalkyl group or 4-, 5- or 6-membered ring containing ~~an~~ a heteroatom selected from O and N;

R^8 and R^9 are independently selected from H, Me and optionally substituted C_1-C_6 alkyl or together form an optionally substituted C_3-C_6 cycloalkyl or an optionally substituted 4-, 5- or 6-membered ring containing a further heteroatom selected from O and N;


wherein the optional substituents of ~~Z, R^3,~~ R^4, R^5, R^6, R^7, R^8 and R^9, when present, are independently selected from OH, C_1-C_3 alkyl, C_1-C_3 alkoxy, C(O)Me, amino, NHMe, NMe$_2$, F ~~or~~ and Cl.

2. A compound according to claim 1~~,~~ wherein R^1 is




~~Y and Z combine to form a 4-, 5- or 6-membered ring that is selected from optionally substituted 3-hydroxycyclobutyl, *N*-acylated azetidine, pyrrolidin-2-one, 1-alkylpyrrolidin-2-one, 3-alkyloxazolidin-2-one, 1-alkylpiperidin-2-one or 3-alkyl-1,3-oxazinan-2-one~~.

3. A compound according to claim 1~~,~~ wherein R^1 is




Y and ~~Z combine to form a 4-, 5- or 6-membered ring that is selected from 3-hydroxycyclobutyl, *N*-acyl azetidine, 1-methylpyrrolidin-2-one, 3-methyloxazolidin-2-one, 1-methylpiperidin-2-one and 3-methyl-1,3-oxazinan-2-one~~.

4. A compound according to any preceding claim wherein X is OR^7, optionally wherein R^7 is Me~~in the instance that Y and Z combine to form a 4-, 5- or 6-membered ring the ring is selected from~~




~~wherein * denotes the site of attachment to the cyclohexyl ring and R^{10} is Me or a C_1-C_6 alkyl group optionally substituted with OH, C_1-C_3 alkyl, C_1-C_3 alkoxy, C(O)Me, amino, NHMe, NMe_2, F or Cl~~.

5. A compound according to any preceding claim ~~1~~ wherein ~~R^2 is~~ R^5 is H, C_1-C_6 alkyl or C_3-C_6 cycloalkyl




~~optionally wherein R^3 and R^4 are methyl~~.

6. A compound according to any preceding claim ~~1~~ wherein R^2 is



optionally wherein ~~Y is N(Me)COMe and Z~~ R^4 is H.

~~7. A compound according to any preceding claim wherein R^1 is~~



~~.~~

~~8. A compound according to any preceding claim wherein X is OR^7.~~

~~9~~7. A compound of ~~f~~Formula (~~A~~Id) according to claim 1 selected from:

~~*N* (Imidazo[1,2-*b*]pyridazin-3-yl) 6-methoxy 2-((5*r*,8*r*) 1-methyl 2-oxo 1-azaspiro[4.5]decan-8-yl) 2*H*-indazole-5-carboxamide;~~

~~*N*-(Imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2-((5*s*,8*s*)-1-methyl-2-oxo-1-azaspiro[4.5]decan-8-yl)-2*H*-indazole-5-carboxamide;~~

~~2-((1*s*,4*s*)-4-(Dimethylcarbamoyl)cyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide;~~

~~2-((1*r*,4*r*) 4-(Dimethylcarbamoyl)cyclohexyl) *N* (imidazo[1,2-*b*]pyridazin-3-yl) 6-methoxy 2*H*-indazole-5-carboxamide;~~

~~2-(2-Hydroxy-2-methylspiro[3.5]nonan-7-yl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~2-((1*s*,4*s*) 4-Hydroxycyclohexyl) *N* (imidazo[1,2-*b*]pyridazin-3-yl) 6-methoxy-2*H*-indazole-5-carboxamide;~~

~~2-((1*r*,4*r*)-4-Hydroxycyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide;~~

~~*rel*-2-((1*S*,3*R*)-3-Hydroxycyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~6-Methoxy-2-(1-methyl-2-oxo-1-azaspiro[4.5]decan-8-yl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~*rel*-2-((1*S*,3*R*)-3-Hydroxycyclohexyl)-6-methoxy-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide - Isomer 1 or Isomer 2;~~

~~6-Cyclopropoxy-2-(2-hydroxy-2-methylspiro[3.5]nonan-7-yl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide - Isomer 1 or Isomer 2;~~

~~6-Cyclopropoxy-2-((1*R*,3*S*)-3-hydroxycyclohexyl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;~~

~~6-Cyclopropoxy-2-((1*S*,3*R*)-3-hydroxycyclohexyl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;~~

~~*rel*-6-Cyclopropoxy-2-((1*S*,3*S*)-3-hydroxycyclohexyl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~2-(2-Acetyl-2-azaspiro[3.5]nonan-7-yl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide;~~

N-(Imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2-((1*s*,4*s*)-4-(*N*-methylacetamido)cyclohexyl)-2*H*-indazole-5-carboxamide;

N-(Imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2-((1*r*,4*r*)-4-(*N*-methylacetamido)cyclohexyl)-2*H*-indazole-5-carboxamide;

6-Methoxy-2-((1*s*,4*s*)-4-(*N*-methylacetamido)cyclohexyl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;

6-Methoxy-2-((1*r*,4*r*)-4-(*N*-methylacetamido)cyclohexyl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;

2-((1*r*,4*r*)-4-(Cyclopropanecarboxamido)cyclohexyl)-6-methoxy-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;

2-((1*s*,4*s*)-4-(Cyclopropanecarboxamido)cyclohexyl)-6-methoxy-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;

~~*rel*-2-((6*R*,7*R*)-2-Acetyl-6-methyl-2-azaspiro[3.5]nonan-7-yl)-6-cyclopropoxy-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~*rel*-2-((6*S*,7*R*)-2-Acetyl-6-methyl-2-azaspiro[3.5]nonan-7-yl)-6-cyclopropoxy-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

6-Cyclopropoxy-2-((1*s*,4*s*)-4-(*N*-methylacetamido)cyclohexyl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;

6-Cyclopropoxy-2-((1*r*,4*r*)-4-(*N*-methylacetamido)cyclohexyl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;

N-(Imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2-((1*S*,2*S*,4*R**)-2-methyl-4-(*N*-methylacetamido) cyclohexyl)-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;

N-(Imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2-((1*R*,2*R*,4*R**)-2-methyl-4-(*N*-methylacetamido) cyclohexyl)-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;

~~*rel*-2-((1*S*,2*S*,4*S*)-4-Hydroxy-2-methylcyclohexyl)-6-methoxy-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~*rel*-2-((1*S*,2*S*,4*R*)-4-Hydroxy-2-methylcyclohexyl)-6-methoxy-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~*rel*-6-Cyclopropoxy-2-((1*S*,2*S*,4*R*)-4-hydroxy-2-methylcyclohexyl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~*rel*-6-Cyclopropoxy-2-((1*S*,2*S*,4*S*)-4-hydroxy-2-methylcyclohexyl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~6-Cyclopropoxy-2-(2-hydroxyspiro[3.5]nonan-7-yl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~2-(4-Hydroxy-4-methylcyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~*rel*-2-((1*S*,3*R*)-3-Hydroxy-3-methylcyclohexyl)-6-methoxy-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~*rel*-2-((1*S*,3*S*)-3-Hydroxy-3-methylcyclohexyl)-6-methoxy-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide - Isomer 1 or Isomer 2;~~

~~*rel*-6-Cyclopropoxy-2-((1*S*,3*R*)-3-hydroxy-3-methylcyclohexyl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~6-Cyclopropoxy-2-((1*s*,4*s*)-4-hydroxycyclohexyl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;~~

~~6-Cyclopropoxy-2-((1*r*,4*r*)-4-hydroxycyclohexyl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;~~

2-((1*R*,4*r*)-4-((*R*)-2-Hydroxy-*N*-methylpropanamido)cyclohexyl)-6-methoxy-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;

2-((1*S*,4*r*)-4-((*S*)-2-Hydroxy-*N*-methylpropanamido)cyclohexyl)-6-methoxy-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;

6-Methoxy-2-((1*R*,2*R*,4*R**)-2-methyl-4-(*N*-methylacetamido)cyclohexyl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide - Isomer 1 or Isomer 2;

6-Methoxy-2-((1*S*,2*S*,4*R**)-2-methyl-4-(*N*-methylacetamido)cyclohexyl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;

~~*rel*-2-((6*S*,7*R*)-2-Acetyl-6-methyl-2-azaspiro[3.5]nonan-7-yl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~*rel*-2-((6*R*,7*R*)-2-Acetyl-6-methyl-2-azaspiro[3.5]nonan-7-yl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~*N*-(Imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2-((5*s*,8*s*)-2-methyl-3-oxo-2-azaspiro[4.5]decan-8-yl)-2*H*-indazole-5-carboxamide;~~

~~*N*-(Imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2-((5*r*,8*r*)-2-methyl-3-oxo-2-azaspiro[4.5]decan-8-yl)-2*H*-indazole-5-carboxamide;~~

~~*rel*-2-((7*R*,8*R*)-2,7-Dimethyl-3-oxo-2-azaspiro[4.5]decan-8-yl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide or *rel*-2-((7*S*,8*S*)-2,7-Dimethyl-3-oxo-2-azaspiro[4.5]decan-8-yl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide - Isomers 1, 2, 3 or 4;~~

~~*N*-(Imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2-(1-methyl-2-oxo-3-oxa-1-azaspiro[4.5]decan-8-yl)-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~*rel*-2-((1*R*,3*R*,4*S*)-4-Hydroxy-3-methylcyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~*rel*-2-((1*S*,3*R*,4*S*)-4-Hydroxy-3-methylcyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~*rel*-2-((1*S*,3*S*,4*S*)-4-Hydroxy-3-methylcyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~*rel*-2-((1*R*,3*S*,4*S*)-4-Hydroxy-3-methylcyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~6-Cyclopropoxy-2-((1*r*,4*r*)-4-hydroxycyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-2*H*-indazole-5-carboxamide;~~

~~6-Cyclopropoxy-2-((1*s*,4*s*)-4-hydroxycyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-2*H*-indazole-5-carboxamide;~~

~~6-Methoxy-2-((5*r*,8*r*)-2-methyl-3-oxo-2-azaspiro[4.5]decan-8-yl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;~~

~~6-Methoxy-2-((5*s*,8*s*)-2-methyl-3-oxo-2-azaspiro[4.5]decan-8-yl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;~~

~~2-((1*R*,2*R*,4*S*)-4-Hydroxy-2-methylcyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide;~~

~~2-((1*R*,2*R*,4*R*)-4-Hydroxy-2-methylcyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide;~~

~~2-((1*S*,2*S*,4*R*)-4-Hydroxy-2-methylcyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide;~~

~~2-((1*S*,2*S*,4*S*)-4-Hydroxy-2-methylcyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide;~~

~~2-((1*R*,2*R*,4*S*)-4-Hydroxy-2,4-dimethylcyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide;~~

~~2-((1*R*,2*R*,4*R*)-4-Hydroxy-2,4-dimethylcyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide;~~

2-((1*S*,4*r*)-4-((*S*)-2-Hydroxy-*N*-methylpropanamido)cyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-*2H*-indazole-5-carboxamide;

2-((1*R*,4*r*)-4-((*R*)-2-Hydroxy-*N*-methylpropanamido)cyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide;

6-Methoxy-2-((1*r*,4*r*)-4-(*N*-methylcyclopropanecarboxamido)cyclohexyl)-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;

2-((1*R*,4*r*)-4-((1*r*,3*R*)-3-Hydroxy-*N*-methylcyclobutane-1-carboxamido)cyclohexyl)-6-methoxy-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;

2-((1*R*,4*r*)-4-((1*s*,3*S*)-3-Hydroxy-*N*-methylcyclobutane-1-carboxamido)cyclohexyl)-6-methoxy-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;

2-((1*r*,4*r*)-4-(2-Hydroxy-*N*,2-dimethylpropanamido)cyclohexyl)-6-methoxy-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;

~~2-(2-Acetyl-2-azaspiro[3.5]nonan-7-yl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-((1*r*,3*r*)-3-methoxycyclobutoxy)-2*H*-indazole-5-carboxamide;~~

~~2-(2-Acetyl-2-azaspiro[3.5]nonan-7-yl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-((1*s*,3*s*)-3-methoxycyclobutoxy)-2*H*-indazole-5-carboxamide;~~

~~2-((1*r*,4*r*)-4-(1*H*-1,2,3-triazol-1-yl)cyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide;~~

~~2-((1*r*,4*r*)-4-(2*H*-1,2,3-triazol-2-yl)cyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide;~~

~~*rel*-2-((1*S*,2*S*,3*R*)-3-Hydroxy-2-methylcyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~*rel*-2-((1*S*,2*R*,3*S*)-3-Hydroxy-2-methylcyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~*rel*-2-((1*S*,2*R*,3*R*)-3-Hydroxy-2-methylcyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

2-((1*S*,4*r*)-4-((*S*)-3-Hydroxy-*N*-methylbutanamido)cyclohexyl)-6-methoxy-*N*-(pyrazolo[1,5-a]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;

2-((1*R*,4*r*)-4-((*R*)-3-Hydroxy-*N*-methylbutanamido)cyclohexyl)-6-methoxy-*N*-(pyrazolo[1,5-a]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide;

rel-2-((1*R*,4*r*)-4-((1*R*,3*R*)-3-Hydroxy-*N*-methylcyclopentane-1-carboxamido)cyclohexyl)-6-methoxy-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;

rel-2-((1*R*,4*r*)-4-((1*R*,3*S*)-3-hydroxy-*N*-methylcyclopentane-1-carboxamido)cyclohexyl)-6-methoxy-*N*-(pyrazolo[1,5-*a*]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;

2-((1*S*,4*r*)-4-((*S*)-3-Hydroxy-*N*-methylpyrrolidine-1-carboxamido)cyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide;

2-((1*R*,4*r*)-4-((*R*)-3-Hydroxy-*N*-methylpyrrolidine-1-carboxamido)cyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide;


~~6-Methoxy-2-(1-methyl-2-oxo-4-oxa-1-azaspiro[5.5]undecan-9-yl)-*N*-(pyrazolo[1,5-a]pyrimidin-3-yl)-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~

~~*rel*-2-((5*R*,7*R*,8*R*)-1,7-dimethyl-2-oxo-1-azaspiro[4.5]decan-8-yl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2 ; and~~

~~*rel*-2-((5*S*,7*R*,8*R*)-1,7-Dimethyl-2-oxo-1-azaspiro[4.5]decan-8-yl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide – Isomer 1 or Isomer 2;~~


or a pharmaceutically acceptable salt thereof.

8. A compound of Formula (Id) according to claim 1 that is *N*-(Imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2-((1*r*,4*r*)-4-(*N*-methylacetamido)cyclohexyl)-2*H*-indazole-5-carboxamide




.

9. A compound of Formula (Id) according to claim 1 that is *N*-(Imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2-((1*R*,2*R*,4*R**)-2-methyl-4-(*N*-methylacetamido)cyclohexyl)-2*H*-indazole-5-carboxamide Isomer 2



.

10. A compound of Formula (Id) according to claim 1 that is 2-((1*R*,4*r*)-4-((*R*)-2-Hydroxy-*N*-methylpropanamido)cyclohexyl)-*N*-(imidazo[1,2-*b*]pyridazin-3-yl)-6-methoxy-2*H*-indazole-5-carboxamide



.

~~10~~11. A pharmaceutical composition comprising a compound of ~~f~~Formula (~~A~~Id) according to any preceding claim and at least one pharmaceutically acceptable excipient.

~~11~~12. A compound of ~~f~~Formula (~~A~~Id) according to any ~~preceding claim~~of claims 1 to 10 for use as a medicament.

~~12~~13. A compound for use according to claim ~~11~~12 for use in the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), of cancer, of inflammatory diseases, and of autoinflammatory/autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjögren's syndrome, systemic sclerosis, gout, endometriosis, atopic dermatitis and psoriasis.

~~13. A compound of formula (A) according to any of claims 1 to 9 for use in the manufacture of a medicament, optionally wherein the medicament is for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), of cancer, of inflammatory diseases and of autoinflammatory/autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjögren's syndrome, systemic sclerosis, gout, endometriosis, atopic dermatitis and psoriasis.~~

~~14. A method of treating diseases or conditions in which inhibition of IRAK4 is beneficial, comprising administering to patient in need thereof an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, according to any of claims 1 to 9 .~~

~~15. Method of treatment according to claim 14 wherein the patient in need is a patient with a respiratory disease such as asthma and chronic obstructive pulmonary disease (COPD), with cancer, with an inflammatory disease or with an autoinflammatory/autoimmune disease such as systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjögren's syndrome, systemic sclerosis, gout, endometriosis, atopic dermatitis and psoriasis.~~

~~16~~14. Compound for use according to claim 12~~11 or claim 13 or method of treatment according to claim 14~~ wherein the use~~, medicament or treatment~~ is for treatment of a haematologic malignancy selected from Waldenstrom's macroglobulinemia (WM), non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), primary central nervous system lymphoma (PCNSL), Splenic Marginal Zone Lymphoma (SMZL), small lymphocytic lymphoma (SLL), leukaemias (chronic lymphocytic leukaemia (CLL)) and monoclonal gammopathy of undetermined significance (MGUS-IgM+).

15. Compound for use according to claim 12 wherein the use is for treatment of asthma, chronic obstructive pulmonary disease, systemic lupus erythematosus, rheumatoid arthritis, myositis, Sjögren's syndrome, systemic sclerosis, gout, endometriosis, atopic dermatitis or psoriasis.